550 related articles for article (PubMed ID: 19259975)
21. Myelodysplastic syndromes: molecular pathogenesis and genomic changes.
Nolte F; Hofmann WK
Ann Hematol; 2008 Oct; 87(10):777-95. PubMed ID: 18516602
[TBL] [Abstract][Full Text] [Related]
22. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
23. [Molecular bases of leukemia, MPD and MDS].
Kitamura T
Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
[No Abstract] [Full Text] [Related]
24. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA
Leuk Res; 2006 Feb; 30(2):233-9. PubMed ID: 16046234
[TBL] [Abstract][Full Text] [Related]
25. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
26. Nuclear inositide signaling in myelodysplastic syndromes.
Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
[TBL] [Abstract][Full Text] [Related]
27. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
28. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
29. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
Sashida G; Harada H; Matsui H; Oshima M; Yui M; Harada Y; Tanaka S; Mochizuki-Kashio M; Wang C; Saraya A; Muto T; Hayashi Y; Suzuki K; Nakajima H; Inaba T; Koseki H; Huang G; Kitamura T; Iwama A
Nat Commun; 2014 Jun; 5():4177. PubMed ID: 24953053
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study.
Aktas D; Tuncbilek E
Cancer Genet Cytogenet; 2006 Nov; 171(1):72-5. PubMed ID: 17074595
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal aberrations in congenital bone marrow failure disorders--an early indicator for leukemogenesis?
Göhring G; Karow A; Steinemann D; Wilkens L; Lichter P; Zeidler C; Niemeyer C; Welte K; Schlegelberger B
Ann Hematol; 2007 Oct; 86(10):733-9. PubMed ID: 17653548
[TBL] [Abstract][Full Text] [Related]
32. [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
Zhang Y; Zhang MR; Yang L; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):470-3. PubMed ID: 17147251
[TBL] [Abstract][Full Text] [Related]
33. NUP98 dysregulation in myeloid leukemogenesis.
Moore MA; Chung KY; Plasilova M; Schuringa JJ; Shieh JH; Zhou P; Morrone G
Ann N Y Acad Sci; 2007 Jun; 1106():114-42. PubMed ID: 17442773
[TBL] [Abstract][Full Text] [Related]
34. [Analyses of the mutations of AML 1 gene in myelodysplastic syndromes].
Yoichi I
Rinsho Ketsueki; 2002 Mar; 43(3):139-45. PubMed ID: 11979742
[No Abstract] [Full Text] [Related]
35. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
[TBL] [Abstract][Full Text] [Related]
36. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
37. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
38. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
[TBL] [Abstract][Full Text] [Related]
39. Fanconi Anemia patient with AML1 gene amplification and monosomy 7 in pre-transplant myelodysplasia (MDS) relapsing 7 years after successful allo-SCT.
Ayas M; Walter C
Bone Marrow Transplant; 2008 Oct; 42(8):555-7. PubMed ID: 18622412
[No Abstract] [Full Text] [Related]
40. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G
Ann N Y Acad Sci; 2006 Nov; 1089():411-23. PubMed ID: 17261784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
